The work suggests that citrullination of glucokinase is a marker of beta cell dysfunction as well as an autoimmune biomarker of T1D and support a potential therapeutic strategy of inhibiting PAD enzymes to restore beta cell metabolic pathways. The gene discussed is GCK; the disease is type 1 diabetes mellitus.